The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials
Open accessAbstract
Purpose: The impact of a personalized cancer treatment strategy (ie, matching patients with drugs based on specific biomarkers) is still a matter of debate. Methods: We reviewed phase II single-agent studies (570 studies; 32,149 patients) published between January 1, 2010, and December 31, 2012 (PubMed search). Response rate (RR), progression-free survival (PFS), and overall survival (OS) were compared for arms that used a personalized strategy versus those that did not. Results: Multivariable analysis (both weighted multiple linear regression and random effects meta-regression) demonstrated that the personalized approach, compared with a nonpersonalized approach, consistently and independently correlated with higher median RR (31% v 10.5%, respectively; P < .001) and prolonged median PFS (5.9 v 2.7 months, respectively; P < .001) and OS (13.7 v 8.9 months, respectively; P < .001). Nonpersonalized targeted arms had poorer outcomes compared with either personalized targeted therapy or cytotoxics, with median RR of 4%, 30%, and 11.9%, respectively; median PFS of 2.6, 6.9, and 3.3 months, respectively (all P < .001); and median OS of 8.7, 15.9, and 9.4 months, respectively (all P < .05). Personalized arms using a genomic biomarker had higher median RR and prolonged median PFS and OS (all P ≤ .05) compared with personalized arms using a protein biomarker. A personalized strategy was associated with a lower treatment-related death rate than a nonpersonalized strategy (median, 1.5% v 2.3%, respectively; P < .001). Conclusion: Comprehensive analysis of phase II, single-agent arms revealed that, across malignancies, a personalized strategy was an independent predictor of better outcomes and fewer toxic deaths. In addition, nonpersonalized targeted therapies were associated with significantly poorer outcomes than cytotoxic agents, which in turn were worse than personalized targeted therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationGefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationFive-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Random-effects model for meta-analysis of clinical trials: An update
DerSimonian, R., & Kacker, R. (2007) · Contemporary Clinical Trials · doi:10.1016/j.cct.2006.04.004 · Cited by 2,374
Falchook, G. S., Long, G. V., Kurzrock, R., Kim, K. B., Arkenau, T. H., Brown, M. P., Hamid, O., Infante, J. R., Millward, M., Pavlick, A. C., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60398-5 · Cited by 943
Self-citationVon Hoff, D. D., Stephenson, J. J., Rosen, P., Loesch, D. M., Borad, M. J., Anthony, S., Jameson, G., Brown, S., Cantafio, N., Richards, D. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5983 · Cited by 647
Discovery of small molecule cancer drugs: Successes, challenges and opportunities
Hoelder, S., Clarke, P. A., & Workman, P. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.02.004 · Cited by 587
Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative
Tsimberidou, A.-M., Iskander, N. G., Hong, D. S., Wheler, J. J., Falchook, G. S., Fu, S., Piha-Paul, S., Naing, A., Janku, F., Luthra, R., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1627 · Cited by 539
Self-citationNew approaches to molecular cancer therapeutics
Collins, I., & Workman, P. (2006) · Nature Chemical Biology · doi:10.1038/nchembio840 · Cited by 391
The Genetic Basis for Cancer Treatment Decisions
Dancey, J. E., Bedard, P. L., Onetto, N., & Hudson, T. J. (2012) · Cell · doi:10.1016/j.cell.2012.01.014 · Cited by 343
Janku, F., Wheler, J. J., Naing, A., Falchook, G. S., Hong, D. S., Stepanek, V. M., Fu, S., Piha-Paul, S. A., Lee, J. J., Luthra, R., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1726 · Cited by 300
Self-citationPersonalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance
Gonzalez de Castro, D., Clarke, P. A., Al-Lazikani, B., & Workman, P. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.237 · Cited by 239
Tsimberidou, A.-M., Wen, S., Hong, D. S., Wheler, J. J., Falchook, G. S., Fu, S., Piha-Paul, S., Naing, A., Janku, F., Aldape, K., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0603 · Cited by 211
Self-citationMichiels, S., Piedbois, P., Burdett, S., Syz, N., Stewart, L., & Pignon, J.-P. (2005) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462305050154 · Cited by 154
Next generation sequencing in cancer research and clinical application
Shyr, D., & Liu, Q. (2013) · Biological Procedures Online · doi:10.1186/1480-9222-15-4 · Cited by 152
Vemurafenib in Melanoma with BRAF V600E Mutation
Dalle, S., Poulalhon, N., & Thomas, L. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1108651 · Cited by 118
Said, R., Hong, D. S., Warneke, C. L., Lee, J. J., Wheler, J. J., Jankú, F., Naing, A., Falchook, G. S., Fu, S., Piha-Paul, S. A., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.974 · Cited by 118
Self-citationUnraveling the Genetics of Cancer: Genome Sequencing and Beyond
Wong, K. M., Hudson, T. J., & McPherson, J. D. (2011) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-082509-141532 · Cited by 107
Stewart, D. J., & Kurzrock, R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9621 · Cited by 104
Self-citationTargeted therapy for HER2 positive breast cancer
Incorvati, J., Shah, S. S., Mu, Y., & Lu, J. M. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-38 · Cited by 97
Review of the Treatment of Non-Small Cell Lung Cancer with Gefitinib
Araki, T., Yashima, H., Shimizu, K., Aomori, T., Hashita, T., Kaira, K., Nakamura, T., & Yamamoto, K. (2012) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s7340 · Cited by 68
It's About Time: Lessons for Solid Tumors from Chronic Myelogenous Leukemia Therapy
Westin, J. R., & Kurzrock, R. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0473 · Cited by 57
Self-citationMolecular Profiling and the Reclassification of Cancer: Divide and Conquer
Munoz, J. L., Swanton, C., & Kurzrock, R. (2013) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2013.33.127 · Cited by 41
Self-citationIs EGFR expression important in non-small cell lung cancer?
Lee, S. M. (2006) · Thorax · doi:10.1136/thx.2005.047936 · Cited by 39
Complete Molecular Remission in Chronic Myelogenous Leukemia after Imatinib Therapy
Barbany, G., Höglund, M., & Simonsson, B. (2002) · New England Journal of Medicine · doi:10.1056/nejm200208153470719 · Cited by 36
A Pilot Study Using Next-Generation Sequencing in Advanced Cancers: Feasibility and Challenges
Weiss, G. J., Liang, W. S., Demeure, M. J., Kiefer, J., Hostetter, G. H., Izatt, T., Sinari, S. A., Christoforides, A., Aldrich, J., Kurdoglu, A. A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076438 · Cited by 32
Jankú, F., Berry, D. A., Gong, J., Parsons, H. A., Stewart, D. J., & Kurzrock, R. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0178 · Cited by 23
Self-citationMelanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes
Henary, H. A., Hong, D. S., Falchook, G. S., Tsimberidou, A. M., George, G. C., Wen, S., Wheler, J. J., Fu, S., Naing, A., Piha-Paul, S. A., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt115 · Cited by 15
Self-citationAre Companion Diagnostics Useful?
Barrett, J. C., Frigault, M. M., Hollingsworth, S. J., Miller, G. A., & Modur, V. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2012.185132 · Cited by 10
Cited by
OncoKB: A Precision Oncology Knowledge Base
Chakravarty, D., Gao, J., Phillips, S., Kundra, R., Zhang, H., Wang, J., Rudolph, J. E., Yaeger, R., Soumerai, T., Nissan, M. H., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00011 · Cited by 2,589
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial
Rodon, J., Soria, J.-C., Berger, R., Miller, W. H., Rubin, E., Kugel, A., Tsimberidou, A., Saintigny, P., Ackerstein, A., Braña, I., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0424-4 · Cited by 578
Self-citationPishvaian, M. J., Blais, E. M., Brody, J. R., Lyons, E., DeArbeloa, P., Hendifar, A., Mikhail, S., Chung, V., Sahai, V., Sohal, D. P. S., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30074-7 · Cited by 548
Treatment selection in depression.
Cohen, Z. D., & DeRubeis, R. J. (2018) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050817-084746 · Cited by 435
Functional precision cancer medicine—moving beyond pure genomics
Letai, A. (2017) · Nature Medicine · doi:10.1038/nm.4389 · Cited by 366
Metadata
- Authors
- Schwaederle, M., Zhao, M., Lee, J. J., Eggermont, A. M., Schilsky, R. L., Mendelsohn, J., Lazar, V., & Kurzrock, R.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-11-10
- Volume
- 33
- Issue
- 32
- Pages
- 3817-3825
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2103724490
- Cited by
- 494
- References
- 34
- FWCI
- 9.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.